Experts

EUVAP Site Network

What is EUVAP?

EUVAP is a platform for experienced clinical trial sites interested in conducting COVID-19 vaccine studies.

Clinical trial sites register with the EUVAP database by answering a short site questionnaire. Any clinical trial site from the European Union and neighbouring countries can register with EUVAP.

The EUVAP platform database is managed by the Clinical Trial Infrastructure of the German Center for Infection Research (DZIF) at the University of Cologne.

What does EUVAP seek to accomplish?

EUVAP aims to accelerate clinical development of COVID-19 vaccines for all populations and risk groups.
The EUVAP database allows for a Europe-wide mapping of experienced clinical trial sites interested in conducting COVID-19 vaccine trials.
EUVAP uses its database to put individual sites in contact with clinical trial sponsors, matching the characteristics of each site with the specific requirements of an individual trial.
EUVAP acts as an information broker or matchmaker between interested sites and sponsors, it is not a governing or management body for trial conduct. EUVAP interacts with established research networks but also with clinical trial sites not affiliated with a network.

EUVAP thereby intends to boost the conduct of clinical trials of any scale across country borders in specific populations and risk groups that are not the focus of ongoing phase III trials. There is no upfront limitation on study design: Studies may be head-to-head interventional or observational, on short-term or long-term outcomes, focusing on very small populations or else. Any sponsor from academia, small or medium enterprises (SME), biotech or pharmaceutical industry is welcome to contact EUVAP. In the long term, EUVAP is designed to roll out vaccine trials in indications beyond COVID-19.

What information will EUVAP ask for when you register your clinical trial site?

  • Name and type of institution, contact details
  • Affiliation with infectious disease networks
  • Prior clinical trial experience
  • Main area of expertise, e.g. disease or indication of interest
  • Infrastructure available at your site
  • Your preferences for COVID-19 vaccine studies, e.g. specific study populations, inpatient vs. outpatient setting etc.
  • You can also share the contacts of other sites you wish to recommend for EUVAP

 

470 clinical trial sites have joined EUVAP so far. The majority is either located in the EU or associated with the H2020 programme.

31 further study sites have expressed interest.

EUVAP laboratories

VACCELERATE Webinars

The VACCELERATE webinars are taking place once a month with a duration of approx. 1 hour. In the webinars different countries present their results on COVID-19 vaccine trials. The webinars are accredited by EACCME (https://eaccme.uems.eu/home.aspx). If you missed the webinar, you can view it on our website. Information about upcoming events can be found on the website as well as on social media. 

VACCELERATE Webinar January 19 2022

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection With Prof. Merryn Voysey, University of Oxford, Oxford Vaccine Group, UK

https://www.youtube.com/watch?v=ZLO6HmMroEU

VACCELERATE Webinar December 16 2021 

Humoral Immune Response in Hemato-oncological Patients, with Prof. Matthias Preusser 

https://www.youtube.com/watch?v=Wct_SPSfQaQ

VACCELERATE Webinar November 18 2021

Vaccine waning and booster protection across ages – data from Israel, with Yair Goldberg and Amit Huppert

https://www.youtube.com/watch?v=Y0S2fjDU7-g&feature=youtu.be

VACCELERATE Webinar October 28 2021

HeVACC Study – Heterologous SARS-CoV-2 Vaccination with Prof. Dorothee von Laer

https://www.youtube.com/watch?v=Sseri78juQw

VACCELERATE Webinar September 15 2021

Com-COV Vaccine Trials, with Prof. Matthew Snape and Emma Plested

https://www.youtube.com/watch?v=VUiioeWaPqg&t=56s

 

VACCELERATE Webinar June 16 2021

Spanish Combivacs Study & VACCELERATE 

https://www.youtube.com/watch?v=ajRKn9AGupY

The COVID-NMA initiative – A living mapping and living systematic review of Covid-19 trials

Launched in March 2020, COVID-NMA is an international initiative working in conjunction with the World Health Organization (WHO), led by a team of researchers from Cochrane and other institutions (Université de Paris, Inserm, CNRS, Centre for Evidence-Based Medicine Odense (CEBMO), University of Southern Denmark, Odense University Hospital, Epistemonkos Foundation, Fondazione IRCCS Ca‘ Granda Ospedale Maggiore Policlinico, University of Milan).

The mission is to inform research planning by producing an up-to-date mapping of trial evidence, to inform public health and healthcare decisions by producing relevant, accessible, up-to-date, and trustworthy synthesis of high-quality evidence  about the efficacy and safety of interventions for the prevention or treatment of COVID-19 and to improve research value by producing a living monitoring of trial planning, conduct, and reporting  and implementing interventions to transform research practices.

For more information: https://covid-nma.com/vaccines/mapping/